Database Query Results : , , CD133

CD133, prominin-1: Click to Expand ⟱
Source:
Type:
CD133, also known as prominin-1, is a pentaspan transmembrane glycoprotein that is commonly used as a marker for stem cells, particularly in the context of cancer research. It is a cell surface protein that is expressed on the surface of many types of stem cells, including embryonic stem cells, hematopoietic stem cells, and cancer stem cells.

CD133 is often used as a marker to identify and isolate cancer stem cells, which are thought to be responsible for the initiation and progression of cancer.

High levels of CD133 expression have been associated with poor prognosis and reduced overall survival in various types of cancer.
Scientific Papers found: Click to Expand⟱
5431- AG,    Advances in research on the anti-tumor mechanism of Astragalus polysaccharides
- Review, Var, NA
AntiTum↑, TumCG↓, TumCI↓, Apoptosis↑, Imm↑, Bcl-2↓, BAX↑, Wnt↓, β-catenin/ZEB1↓, TumCG↓, miR-133a-3p↑, JNK↓, Fas↑, P53↑, P21↑, NOTCH1↓, NOTCH3↓, TumCP↓, TumCCA↑, GPx4↓, xCT↓, AMPK↑, Beclin-1↑, NF-kB↓, EMT↓, Vim↓, TumMeta↓, VEGF↓, EGFR↓, eff↑, eff↑, MMP↓, P-gp↓, MMP9↓, ChemoSen↑, SIRT1↓, SREBP1↓, TumAuto↑, PI3K↓, mTOR↓, Casp3↑, Casp9↑, CD133↓, CD44↓, CSCs↓, QoL↑,
5437- AG,    Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion
- in-vivo, Melanoma, B16-F10
CSCs↓, CD133↓, BMI1↓, PD-L1↓, TumCG↓,
5380- ART/DHA,    Artemisinin and Its Derivatives as Potential Anticancer Agents
- Review, Var, NA
TumCG↓, angioG↓, Ferroptosis↑, TumCP↑, TumAuto↑, CSCs↑, eff↑, YAP/TEAD↓, TumCCA↑, ROS↑, ChemoSen↑, N-cadherin↓, Vim↓, MMP9↓, eff↑, STAT3↓, CD133↓, CD44↓, Nanog↓, cMyc↓, OCT4↓, Akt↓, mTOR↓,
4658- BBR,    Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
CSCs↓, TumCP↓, cycD1/CCND1↓, p27↑, P21↑, TumCCA↑, Apoptosis↑, ChemoSen↑, β-catenin/ZEB1↓, FTO↑, CD44↓, CD133↓, ChemoSen↑,
2685- BBR,    Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells
- in-vitro, neuroblastoma, NA
CSCs↓, CD133↓, β-catenin/ZEB1↓, n-MYC↓, SOX2↓, NOTCH2↓, Nestin↓, TumCCA↑, TumCP↓, CDK1↓, Cyc↓, Apoptosis↑, Bax:Bcl2↑, NCAM↓, MMP2↓, MMP9↓, *Smad1↑, *HSP70/HSPA5↑, *LAMs↑,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
1584- Citrate,    Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations
- in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1
tumCV↓, i-Ca+2↓, TumCMig↓, CD133↓, pH↑, eff↑, Ki-67↓, eff↑,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
431- CUR,    Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
ALDH1A1↓, CD133↓, EpCAM↓, OCT4↓, TAZ↓, Hippo↑, p‑TAZ↑,
10- CUR,    Curcumin Suppresses Lung Cancer Stem Cells via Inhibiting Wnt/β-catenin and Sonic Hedgehog Pathways
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
HH↓, Wnt/(β-catenin)↓, Shh↓, Smo↓, Gli1↝, GLI2↝, CSCs↓, CD133↓, CSCsMark↓,
3243- EGCG,    (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway
CD133↓, CSCs↓, TumCP↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓,
4681- EGCG,    Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling
- in-vitro, Ovarian, ES-2
TumCP↓, Apoptosis↑, Nanog↓, SOX2↓, Fibronectin↓, CD133↓,
4682- EGCG,    Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate
- Review, Var, NA
CSCs↓, EMT↓, ChemoSen↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, TumCP↓, Apoptosis↑, p‑GSK‐3β↓, GSK‐3β↑, β-catenin/ZEB1↓, cMyc↓, XIAP↓, Bcl-2↓, survivin↓, Vim↓, Slug↓, Snail↓,
4683- EGCG,    Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vivo, Lung, A549
CSCs↓, CD133↓, CLOCK↓, Wnt↓, β-catenin/ZEB1↓, CD44↓, SOX2↓, Nanog↓, OCT4↓,
1247- EMD,    Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition
- vitro+vivo, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓, CSCs↓,
2511- H2,    Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation
- in-vivo, GBM, U87MG
TumCG↓, OS↑, CD133↓, Ki-67↓, angioG↓, Diff↑, TumCMig↓, TumCI↓, Dose↝, BBB↑, mt-ROS↑,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
4956- PEITC,    Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells
- vitro+vivo, Lung, A549
GSH↓, ROS↑, mtDam↑, mitResp↓, MMP↓, CSCs↓, OCT4↓, ABC↓, SOX2↓, CD133↓, CD44↓, ALDH↓, Nanog↓, TumCG↓,
4701- PTS,  RES,    Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene
- Review, Var, NA
CSCs↓, E-cadherin↑, NF-kB↓, EMT↓, GRP78/BiP↓, CD133↓, COX2↓, β-catenin/ZEB1↓, NOTCH↓,
4696- PTS,    BlueBerry Isolate, Pterostilbene, Functions as a Potential Anticancer Stem Cell Agent in Suppressing Irradiation-Mediated Enrichment of Hepatoma Stem Cells
- in-vitro, HCC, NA
CD133↓, CSCs↓,
4692- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
- in-vitro, Cerv, HeLa
TumCG↓, TumMeta↓, TumCCA↑, ROS↑, Apoptosis↑, MMP2↓, MMP9↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, CSCs↓,
4689- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
eff↑, TumCCA↑, ROS↑, MMP2↓, MMP9↓, CSCs↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, BioAv↑, TumCI↓, ROS↑, Apoptosis↑,
58- QC,  doxoR,    Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin
- in-vitro, CRC, HT-29 - in-vitro, NA, CD133+
Bcl-2↓, TumCCA↑, CD133↓, CSCs↓, ChemoSen↑, CycB/CCNB1↑, cycE/CCNE↓, cycD1/CCND1↓, E2Fs↓,
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓, CD44↓, CD133↓, CSCs↓,
4657- RES,    Resveratrol, cancer and cancer stem cells: A review on past to future
- Review, Var, NA
CSCs↓, CD133↓, Shh↓, Twist↓, Snail↓, MMP2↓, MMP9↓, Smad1↓, CD44↓, ALDH1A1↓, OCT4↓, Nanog↓, STAT3↓, survivin↓, cycD1/CCND1↓, COX2↓, cMyc↓,
4663- RES,    Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models
- Review, Var, NA
*antiOx↑, *Inflam↓, *chemoPv↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, NOTCH↓, PI3K↓, Akt↓, mTOR↓, GSK‐3β↝, Snail↓, HH↓, p‑GSK‐3β↓, N-cadherin↓, EMT↓, CD133↓, CD44↓, ALDH1A1↓, OCT4↓, SOX4↓, Shh↓, Smo↓, Gli1↓, GLI2↓,
4662- RES,    A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
CSCs↓, CD133↓, OCT4↓, β-catenin/ZEB1↓, HER2/EBBR2↓, TumCP↓, PI3K↓, Akt↓, ALDH1A1↓, eff↑,
105- RES,  QC,    The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell
- in-vitro, Pca, PANC1
N-cadherin↓, TNF-α↓, ACTA2↓, EMT↓, CD133↓, CSCs↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
3199- SFN,    Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis
- in-vitro, GC, NA
CSCs↓, CD133↓, BMI1↓, Nanog↓, Nestin↓,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1/CCND1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT/TERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
631- VitC,    Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2
- vitro+vivo, Liver, NA
SVCT-2∅, ROS↑, DNAdam↑, ATP↓, TumCCA↑, Apoptosis↑, OS↑, CD133↓, EpCAM↓, OV6↓, γH2AX↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 38

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   GSTA1↑, 1,   HO-1↑, 1,   NRF2↑, 3,   ROS↓, 1,   ROS↑, 11,   mt-ROS↑, 1,   SIRT3↑, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 2,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 1,   mitResp↓, 1,   MMP↓, 5,   mtDam↑, 1,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 6,   Glycolysis↓, 1,   p‑S6K↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 1,   Apoptosis↑, 14,   BAX↑, 3,   Bax:Bcl2↑, 2,   Bcl-2↓, 7,   Casp3↑, 6,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 5,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 2,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   Hippo↑, 1,   hTERT/TERT↓, 1,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 2,   Mcl-1↑, 1,   p27↑, 3,   p38↓, 2,   survivin↓, 5,   Telomerase↓, 1,   TRAILR↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

EF-1α↓, 1,   HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   H3↑, 1,   H4↑, 1,   HATs↑, 1,   OV6↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   cl‑CHOP↑, 1,   eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   p‑PERK↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   DNMT1↓, 1,   DNMT3A↓, 1,   P53↑, 3,   cl‑PARP↑, 2,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK1↑, 1,   CDK2↓, 3,   CDK4↓, 3,   Cyc↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 6,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 2,   E2Fs↓, 1,   P21?, 1,   P21↑, 3,   p‑RB1↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 2,   ALDH1A1↓, 7,   BMI1↓, 2,   CD133↓, 38,   CD44↓, 16,   CLOCK↓, 1,   p‑cMET↑, 1,   CSCs↓, 30,   CSCs↑, 1,   CSCsMark↓, 1,   Diff↓, 1,   Diff↑, 1,   EMT↓, 13,   EpCAM↓, 2,   ERK↓, 4,   p‑ERK↓, 2,   Gli1↓, 1,   Gli1↝, 1,   GSK‐3β↑, 1,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 3,   HH↓, 2,   LGR5↓, 1,   mTOR↓, 5,   mTORC1↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 2,   Nanog↓, 12,   Nestin↓, 6,   NOTCH↓, 4,   NOTCH1↓, 2,   NOTCH2↓, 1,   NOTCH3↓, 2,   OCT4↓, 13,   PI3K↓, 6,   p‑PI3K↓, 1,   PTEN↑, 2,   RAS↑, 1,   Shh↓, 4,   Smo↓, 2,   SOX2↓, 9,   STAT3↓, 7,   p‑STAT3↓, 2,   TAZ↓, 1,   p‑TAZ↑, 1,   TumCG↓, 10,   Wnt↓, 5,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

ACTA2↓, 1,   i-Ca+2↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   Fibronectin↓, 1,   FTO↑, 1,   GLI2↓, 1,   GLI2↝, 1,   ITGB1↓, 1,   Ki-67↓, 3,   LEF1↓, 1,   miR-133a-3p↑, 1,   MMP2↓, 8,   MMP9↓, 9,   MMPs↓, 2,   N-cadherin↓, 5,   NCAM↓, 1,   PKCδ↓, 1,   Slug↓, 2,   Smad1↓, 1,   Snail↓, 4,   SOX4↓, 2,   TET1↓, 1,   TumCI↓, 11,   TumCMig↓, 9,   TumCP↓, 9,   TumCP↑, 1,   TumMeta↓, 4,   Twist↓, 2,   uPA↓, 2,   Vim↓, 5,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 11,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 5,   Hif1a↓, 3,   VEGF↓, 4,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 2,   SVCT-2∅, 1,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 4,   CXCR4↓, 2,   IKKα↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 2,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 9,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 3,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Drug Metabolism & Resistance ⓘ

ABC↓, 1,   ABCG2↓, 1,   BioAv↓, 2,   BioAv↑, 2,   ChemoSen↑, 10,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 2,   eff↑, 12,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   P450↓, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

BMPs↑, 1,   EGFR↓, 5,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 3,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   chemoP↑, 1,   OS↑, 3,   QoL↑, 1,   TumVol↓, 1,  
Total Targets: 233

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 1,   GSH↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 3,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   NADPH↓, 1,  

Cell Death ⓘ

Casp3↓, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   HDAC3↓, 1,  

Migration ⓘ

Ki-67↓, 1,   LAMs↑, 1,   p‑Rac1↓, 1,   Smad1↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IKKα↑, 1,   IL10↓, 1,   IL6↓, 1,   Inflam↓, 3,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   RenoP↑, 1,  
Total Targets: 36

Scientific Paper Hit Count for: CD133, prominin-1
6 Resveratrol
5 EGCG (Epigallocatechin Gallate)
4 Pterostilbene
4 Quercetin
3 Berberine
3 Curcumin
3 Honokiol
2 Astragalus
2 Fisetin
2 Sulforaphane (mainly Broccoli)
1 Artemisinin
1 Citric Acid
1 Emodin
1 Hydrogen Gas
1 Magnetic Fields
1 Phenethyl isothiocyanate
1 doxorubicin
1 isoflavones
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:677  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page